The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Open accessAbstract
Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profiling for hundreds of known cancer genes using the FoundationOne™ or FoundationOne Heme™ comprehensive genomic profiling assays. BRA F fusions involving the intact in‐frame BRAF kinase domain were observed in 55 (0.3%) of 20,573 tumors, across 12 distinct tumor types, including 20 novel BRAF fusions. These comprised 29 unique 5′ fusion partners, of which 31% (9) were known and 69% (20) were novel. BRAF fusions included 3% (14/531) of melanomas; 2% (15/701) of gliomas; 1.0% (3/294) of thyroid cancers; 0.3% (3/1,062) pancreatic carcinomas; 0.2% (8/4,013) nonsmall‐cell lung cancers and 0.2% (4/2,154) of colorectal cancers, and were enriched in pilocytic (30%) vs. nonpilocytic gliomas (1%; p < 0.0001), Spitzoid (75%) vs. nonSpitzoid melanomas (1%; p = 0.0001), acinar (67%) vs. nonacinar pancreatic cancers (<1%; p < 0.0001) and papillary (3%) vs. nonpapillary thyroid cancers (0%; p < 0.03). Clinical responses to trametinib and sorafenib are presented. In conclusion, BRAF fusions are rare driver alterations in a wide variety of malignant neoplasms, but enriched in Spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 5×
“Base substitution detection is performed using a Bayesian methodology, which allows detection of novel somatic mutations at low mutant allele frequency (MAF) and increased sensitivity for mutations at hotspot sites through the incorporation of tissue-specific prior expectations.(15) Reads with mapping quality <25 are…”
BackgroundMethodInfluentialDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Paik, P. K., Arcila, M. E., Fara, M., Sima, C. S., Miller, V. A., Kris, M. G., Ladanyi, M., & Riely, G. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1280 · Cited by 691
Self-citationHow to apply de Bruijn graphs to genome assembly
Compeau, P. E. C., Pevzner, P. A., & Tesler, G. (2011) · Nature Biotechnology · doi:10.1038/nbt.2023 · Cited by 673
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
Wiesner, T., He, J., Yelensky, R., Esteve-Puig, R., Botton, T., Yeh, I., Lipson, D., Otto, G., Brennan, K., Murali, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4116 · Cited by 649
Self-citationHaroche, J., Cohen-Aubart, F., Emile, J.-F., Arnaud, L., Maksud, P., Charlotte, F., Cluzel, P., Drier, A., Hervier, B., Benameur, N., et al. (2013) · Blood · doi:10.1182/blood-2012-07-446286 · Cited by 537
Targeting the RAF–MEK–ERK pathway in cancer therapy
Montagut, C., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 468
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Palanisamy, N., Ateeq, B., Kalyana-Sundaram, S., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, Q., Cao, X., Suleman, K., et al. (2010) · Nature Medicine · doi:10.1038/nm.2166 · Cited by 464
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
Ciampi, R., Knauf, J. A., Kerler, R., Gandhi, M., Zhu, Z., Nikiforova, M. N., Rabes, H. M., Fagin, J. A., & Nikiforov, Y. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523237 · Cited by 461
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Cantwell-Dorris, E. R., O'Leary, J. J., & Sheils, O. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0799 · Cited by 459
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Yokota, T., Ura, T., Shibata, N., Takahari, D., Shitara, K., Nomura, M., Kondo, C., Mizota, A., Utsunomiya, S., Muro, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.19 · Cited by 401
Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma
Goel, V. K., Lazar, A. J. F., Warneke, C. L., Redston, M. S., & Haluska, F. G. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700026 · Cited by 392
Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Ichimura, K., & Collins, V. P. (2009) · Oncogene · doi:10.1038/onc.2009.73 · Cited by 321
Haroche, J., Cohen-Aubart, F., Emile, J.-F., Maksud, P., Drier, A., Tolédano, D., Barete, S., Charlotte, F., Cluzel, P., Donadieu, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1950 · Cited by 289
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
Karajannis, M. A., Legault, G., Fisher, M. J., Milla, S. S., Cohen, K. J., Wisoff, J. H., Harter, D. H., Goldberg, J. D., Hochman, T., Merkelson, A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou059 · Cited by 223
Chmielecki, J., Hutchinson, K. E., Frampton, G. M., Chalmers, Z. R., Johnson, A., Shi, C., Elvin, J., Ali, S. M., Ross, J. S., Basturk, O., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0617 · Cited by 189
Self-citationGlioma Biology and Molecular Markers
Cohen, A. L., & Colman, H. (2015) · Cancer Treatment and Research · doi:10.1007/978-3-319-12048-5_2 · Cited by 185
Hutchinson, K. E., Lipson, D., Stephens, P. J., Otto, G., Lehmann, B. D., Lyle, P. L., Vnencak-Jones, C. L., Ross, J. S., Pietenpol, J. A., Sosman, J. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1746 · Cited by 181
Self-citationActivating MET kinase rearrangements in melanoma and Spitz tumours
Yeh, I., Botton, T., Talevich, E., Shain, A. H., Sparatta, A. J., de la Fouchardiere, A., Mully, T. W., North, J. P., Garrido, M. C., Gagnon, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms8174 · Cited by 167
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms
Tran, N. H., Wu, X., & Frost, J. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501185200 · Cited by 153
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
Botton, T., Yeh, I., Nelson, T. A., Vemula, S. S., Sparatta, A. J., Garrido, M. C., Allégra, M., Rocchi, S., Bahadoran, P., McCalmont, T. H., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12148 · Cited by 147
Dadu, R., Shah, K. B., Busaidy, N. L., Waguespack, S. G., Habra, M. A., Ying, A. K., Hu, M. I.-N., Bassett, R. L., Jiménez, C., Sherman, S. I., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2246 · Cited by 131
Pettirossi, V., Santi, A., Imperi, E., Russo, G., Pucciarini, A., Bigerna, B., Schiavoni, G., Fortini, E., Rosseto, A. S., Sportoletti, P., et al. (2014) · Blood · doi:10.1182/blood-2014-10-603100 · Cited by 109
BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
El-Osta, H. E., Falchook, G. S., Tsimberidou, A. M., Hong, D. S., Naing, A., Kim, K., Wen, S., Jankú, F., & Kurzrock, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025806 · Cited by 98
Menzies, A. M., Yeh, I., Botton, T., Bastian, B. C., Scolyer, R. A., & Long, G. V. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12388 · Cited by 86
Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease
Vultur, A., Villanueva, J., & Herlyn, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0174 · Cited by 76
Subbiah, V., Westin, S. N., Wang, K., Araujo, D. M., Wang, W., Miller, V. A., Ross, J. S., Stephens, P. J., Palmer, G. A., & Ali, S. M. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-8 · Cited by 73
Self-citationLee, N. V., Lira, M. E., Pavlı́ček, A., Ye, J., Buckman, D., Bagrodia, S., Srinivasa, S. P., Zhao, Y., Aparicio, S. A. J. R., Rejto, P. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039653 · Cited by 50
Baitei, E. Y., Zou, M., Al-Mohanna, F. A., Collison, K., Alzahrani, A. S., Farid, N. R., Meyer, B. F., & Shi, Y. (2008) · The Journal of Pathology · doi:10.1002/path.2496 · Cited by 39
Passeron, T., Lacour, J. ‐., Allégra, M., Ségalen, C., Deville, A., Thyss, A., Giacchero, D., Ortonne, J. P., Bertolotto, C., Ballotti, R., et al. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01385.x · Cited by 23
Cited by
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
The emerging clinical relevance of genomics in cancer medicine
Berger, M. F., & Mardis, E. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0002-6 · Cited by 626
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M., & Watson, I. R. (2018) · Oncogene · doi:10.1038/s41388-018-0171-x · Cited by 550
Accurate and efficient detection of gene fusions from RNA sequencing data
Uhrig, S., Ellermann, J., Walther, T., Burkhardt, P., Fröhlich, M., Hutter, B., Toprak, U. H., Neumann, O., Stenzinger, A., Scholl, C., et al. (2021) · Genome Research · doi:10.1101/gr.257246.119 · Cited by 526
Metadata
- Authors
- Ross, J. S., Wang, K., Chmielecki, J., Gay, L., Johnson, A., Chudnovsky, J., Yelensky, R., Lipson, D., Ali, S. M., Elvin, J. A., Vergilio, J., Roels, S., Miller, V. A., Nakamura, B. N., Gray, A., Wong, M. K., & Stephens, P. J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2015-09-08
- Volume
- 138
- Issue
- 4
- Pages
- 881-890
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1918248652
- Cited by
- 351
- References
- 38
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.